Clinical trial
A Phase 4, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
NCT00863707 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 4, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
- Lead sponsor
- Astellas Pharma Inc
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 30, 2009
- Completion date
- December 31, 2009
- Enrollment
- 511 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.